MELBOURNE, AUSTRALIA–Celgene Pty and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia.
Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia.
“By combining forces with Juno Pharmaceuticals, we are complementing our innovative product with a strong national key account management team that has relationships across the hospital market,” said George Varkanis, Celgene Vice President and Managing Director (Australia and New Zealand).
The partnership continues the trend for Juno Pharmaceuticals in partnering with leading global pharmaceutical companies. It follows a recent announcement that Juno Pharmaceuticals made with Photocure ASA to bring the unique product Hexvix® to the Australian and New Zealand markets.
“We look forward to delivering a strong partnership model with Celgene on Vidaza® and exploring any opportunities that exist throughout the products lifecycle,” said Juno Pharmaceuticals CEO George Katsanos.
Financial details of the joint venture were not disclosed.
For more information please visit www.junopharm.com.au.